Bone and renal safety of initial antiviral therapy using tenofovir alafenamide fumarate or entecavir for chronic hepatitis B

Table 5 Inter-group comparison of bone and renal safety indexes at the 96-week follow-up, mean ± SD/median (Q1, Q3)

General information	TAF group (n = 45)	ETV group (n = 50)	Total (n = 95)	t value	P value
Serum calcium	2.33 ± 0.12	2.41 ± 0.47	2.37 ± 0.35	0.637	0.529
Serum phosphorus	1.11 ± 0.40	1.00 ± 0.16	1.06 ± 0.30	0.945	0.353
Serum 25-hydroxyvitamin D3	22.15 ± 7.23	25.18 ± 10.11	23.78 ± 8.86	0.863	0.397
Blood urea	4.63 (3.94, 4.94)	4.57 (3.89, 5.22)	4.57 (3.94, 5.18)	0.258	0.797
Serum creatinine	62.00 (59.00, 67.00)	66.00 (58.00, 73.50)	64.00 (58.00, 70.50)	0.890	0.376
Serum retinol-binding protein	48.10 (39.30, 53.70)	42.15 (35.23, 44.90)	43.00 (37.00, 49.40)	0.867	0.388
Serum cystatin C	0.69 (0.52, 0.81)	0.72 (0.67, 0.88)	0.70 (0.66, 0.87)	1.745	0.084
Urinary α1-microglobulin	6.42 (5.27, 7.40)	7.52 (5.71, 9.44)	6.84 (5.34, 8.32)	2.022	0.046
Urine N-acetyl-beta-D-glucosaminidase	6.54 (5.60, 7.25)	8.48 (6.56, 9.96)	7.45 (6.03, 9.11)	3.193	0.002
Urine cystatin	0.11 (0.08, 0.13)	0.14 (0.12, 0.17)	0.13 (0.11, 0.15)	3.561	0.001

TAF: Tenofovir alafenamide fumarate; ETV: Entecavir.